{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:45:17Z","timestamp":1773855917134,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.remnie.2025.500208","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:06:18Z","timestamp":1758704778000},"page":"500208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteria"],"prefix":"10.1016","volume":"45","author":[{"given":"E.","family":"Ozkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Soydal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Araz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.O.","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Urun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500208_bib0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.remnie.2025.500208_bib0010","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remnie.2025.500208_bib0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.remnie.2025.500208_bib0020","unstructured":"FDA approves Pluvicto for metastatic castration-resistant prostate cancer | FDA n.d. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer [Accessed 28 July 2024]."},{"key":"10.1016\/j.remnie.2025.500208_bib0025","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.remnie.2025.500208_bib0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2967\/jnumed.123.267234","article-title":"RECIP 1.0 predicts progression-free survival after [177Lu]Lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500208_bib0035","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","article-title":"PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors","volume":"64","author":"Shagera","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500208_bib0040","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500208_bib0045","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","article-title":"PSMA PET tumor-to-salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study","volume":"64","author":"Hotta","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500208_bib0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","article-title":"Pre-treatment 68 Ga-PSMA-11 PET\/CT prognostic value in predicting response to 177Lu-PSMA-I&T therapy and patient survival","volume":"26","author":"Eisazadeh","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.remnie.2025.500208_bib0055","article-title":"Baseline [68Ga]Ga-PSMA-11 PET\/CT before [177Lu]Lu-PSMA-617 radioligand therapy: value of PSMA-uptake thresholds in predicting targetable lesions","volume":"15","author":"Groener","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.remnie.2025.500208_bib0060","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.remnie.2025.500208_bib0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2025.500208_bib0070","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.123.267014","article-title":"Development of a visually calculated SUVmean (HIT Score) on screening PSMA PET\/CT to predict treatment response to 177Lu-PSMA therapy: comparison with quantitative SUVmean and patient outcomes","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500208_bib0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.123.266702","article-title":"Prognostic performance of RECIP 1.0 based on [18F]PSMA-1007 PET in prostate cancer patients treated with [177Lu]Lu-PSMA I&T","volume":"65","author":"Hartrampf","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:23:14Z","timestamp":1772356994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2253808925001351"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500208","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteria","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500208","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500208"}}